Overall survival at 4 years of follow-up in a phase III trial of nivolumab plus ipilimumab combination therapy in advanced melanoma (CheckMate 067)

被引：0

作者：

Hodi, F. S. ^{[1
]}

Chiarion-Sileni, V. ^{[2
]}

Gonzalez, R. ^{[3
]}

Grob, J. J. ^{[4
,5
]}

Rutkowski, P. ^{[6
]}

Cowey, C. L. ^{[7
]}

Lao, C. ^{[8
]}

Schadendorf, D. ^{[9
,10
]}

Wagstaff, J. ^{[11
]}

Dummer, R. ^{[12
]}

Ferrucci, P. F. ^{[13
]}

Smylie, M. ^{[14
]}

Hill, A. G. ^{[15
]}

Hogg, D. ^{[16
]}

Marquez-Rodas, I. ^{[17
]}

Jiang, J. ^{[18
]}

Rizzo, J. ^{[19
]}

Larkin, J. ^{[20
]}

Wolchok, J. ^{[21
,22
]}

机构：

[1] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA

[2] IRCCS, IOV, Melanoma & Esophageal Canc Unit, Padua, Italy

[3] Univ Colorado, Ctr Canc, Div Med Oncol, Denver, CO 80262 USA

[4] Aix Marseille Univ, Serv Dermatol, Marseille, France

[5] Hosp CHU Timone, AP HM, Marseille, France

[6] Maria Sklodowska Curie Inst, Ctr Oncol, Dept Soft Tissue Bone Sarcoma & Melanoma, Warsaw, Poland

[7] Baylor Charles A Sammons Canc Ctr, Texas Oncol, Melanoma & Genitourinary Oncol Program, Dallas, TX USA

[8] Univ Michigan, Oncol, Ann Arbor, MI 48109 USA

[9] Univ Essen Gesamthsch, Hautklin, Dept Dermatol, Essen, Germany

[10] German Canc Consortium, Essen, Germany

[11] Swansea Univ, Coll Med, Med Oncol, Swansea, W Glam, Wales

[12] Univ Spital, Dermatol, Zurich, Switzerland

[13] European Inst Oncol, Oncol, Milan, Italy

[14] Cross Canc Inst, Dept Oncol, Edmonton, AB, Canada

[15] Tasman Oncol Res, Med Oncol, Southport, Qld, Australia

[16] Princess Margaret Canc Ctr, Med Oncol & Hematol, Toronto, ON, Canada

[17] Gen Univ Hosp Gregorio Maranon, Med Oncol, Madrid, Spain

[18] Bristol Myers Squibb, Global Biometr Sci, Princeton, NJ USA

[19] Bristol Myers Squibb, Oncol Clin Dev, Princeton, NJ USA

[20] Royal Marsden Hosp NHS Fdn Trust, Med, London, England

[21] Mem Sloan Kettering Canc Ctr, Melanoma & Immunotherapeut, 1275 York Ave, New York, NY 10021 USA

[22] Weill Cornell Med Coll, New York, NY USA

来源：

ANNALS OF ONCOLOGY | 2018年 / 29卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA44

引用

页码：735 / 735

页数：1

共 50 条

[21] Overall survival at 5 years of follow-up from a phase 3 trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma
Ascierto, Paolo A.
Del Vecchio, Michele
Mackiewicz, Andrzej
Robert, Caroline
Chiarion-Sileni, Vanna
Arance, Ana
Lebbe, Celeste
Svane, Inge Marie
McNeil, Catriona
Rutkowski, Piotr
Loquai, Carmen
Mortier, Laurent
Hamid, Omid
Bastholt, Lars
Dreno, Brigitte
Schadendorf, Dirk
Garbe, Claus
Nyakas, Marta
Grob, Jean-Jacques
Thomas, Luc
Liszkay, Gabriella
Smylie, Michael
Burcin, Simsek
Hosein, Fareeda
Maio, Michele
JOURNAL OF TRANSLATIONAL MEDICINE, 2019, 17
[22] Association between tumor shrinkage and overall survival in advanced melanoma patients with nivolumab in combination with ipilimumab
Feng, Yan
Gupta, Manish
Agrawal, Shruti
Roy, Amit
CANCER RESEARCH, 2015, 75
[23] Efficacy and quality of life outcomes in patients with advanced melanoma (MEL) who discontinued treatment with nivolumab (NIVO) plus ipilimumab (IPI) due to toxicity in a phase 3 trial (CheckMate 067)
Schadendorf, D.
Larkin, J.
Chiarion-Sileni, V.
Gonzalez, R.
Rutkowski, P.
Grob, J. -J.
Cowey, C. L.
Lao, C.
Taylor, F.
Sabater, J.
Walker, D.
Bhore, R.
Wolchok, J.
Hodi, F. S.
MELANOMA RESEARCH, 2016, 26 : E4 - E4
[24] Cost-Utility of Nivolumab Plus Ipilimumab in First-Line Treatment of Advanced Melanoma in the United States: An Analysis Using Long-Term Overall Survival Data from Checkmate 067
Timothy Baker
Helen Johnson
Srividya Kotapati
Andriy Moshyk
Melissa Hamilton
Murat Kurt
Victoria Federico Paly
PharmacoEconomics - Open, 2022, 6 : 697 - 710
[25] Cost-Utility of Nivolumab Plus Ipilimumab in First-Line Treatment of Advanced Melanoma in the United States: An Analysis Using Long-Term Overall Survival Data from Checkmate 067
Baker, Timothy
Johnson, Helen
Kotapati, Srividya
Moshyk, Andriy
Hamilton, Melissa
Kurt, Murat
Paly, Victoria Federico
PHARMACOECONOMICS-OPEN, 2022, 6 (05) : 697 - 710
[26] UPDATED RESULTS FROM A PHASE 3 TRIAL OF NIVOLUMAB (NIVO) COMBINED WITH IPILIMUMAB (IPI) IN TREATMENT-NAIVE PATIENTS WITH ADVANCED MELANOMA (MEL) (CheckMate 067)
Wolchok, Jedd D.
Chiarion-Sileni, Vanna
Gonzalez, Rene
Rutkowski, Piotr
Grob, Jean-Jacques
Cowey, C. Lance
Lao, Christopher D.
Schadendorf, Dirk
Ferrucci, Pier F.
Smylie, Michael
Dummer, Reinhard
Hill, Andrew
Haanen, John
Maio, Michele
McArthur, Grant
Walker, Dana
Jiang, Joel
Horak, Christine
Larkin, James
Hodi, Stephen
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2016, 12 : 127 - 128
[27] Thirty-month follow-up of the phase III CheckMate 214 trial of first-line nivolumab plus ipilimumab (N plus I) or sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC).
Tannir, Nizar M.
Frontera, Osvaldo Aren
Hammers, Hans J.
Carducci, Michael Anthony
McDermott, David F.
Salman, Pamela
Escudier, Bernard
Beuselinck, Benoit
Amin, Asim
Porta, Camillo
George, Saby
Bracarda, Sergio
Tykodi, Scott S.
Powles, Thomas
Rini, Brian I.
Tomita, Yoshihiko
McHenry, M. Brent
Mekan, Sabeen Fatima
Motzer, Robert J.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
[28] Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma: subgroup analyses from CheckMate 040
Sangro, Bruno
He, Aiwu Ruth
Yau, Thomas
Hsu, Chiun
Kang, Yoon-Koo
Kim, Tae-You
Santoro, Armando
Melero, Ignacio
Kudo, Masatoshi
Ho, Ming-Mo
Matilla, Ana
Tovoli, Francesco
Knox, Jennifer
El-Rayes, Bassel
Acosta, Mirelis Rivera
Neely, Jaclyn
Shen, Yun
Tschaika, Marina
El-Khoureiry, Anthony
JOURNAL OF HEPATOLOGY, 2020, 73 : S121 - S122
[29] Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma (vol 8, e000391, 2020)
Ascierto, P. A.
Del Vecchio, M.
Mackiewicz, A.
Robert, Caroline
Chiarion-Sileni, Vanna
Arance, Ana
Lebbe, Celeste
Svane, Inge Marie
McNeil, Catriona
Rutkowski, Piotr
Loquai, Carmen
Mortier, Laurent
Hamid, Omid
Bastholt, Lars
Dreno, Brigitte
Schadendorf, Dirk
Garbe, Claus
Nyakas, Marta
Grob, Jean-Jacques
Thomas, Luc
Liszkay, Gabriella
Smylie, Michael
Hoeller, Christoph
Ferraresi, Virginia
Grange, Florent
Gutzmer, Ralf
Pikiel, Joanna
Hosein, Fareeda
Simsek, Burcin
Maio, Michele
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (02)
[30] Treatment-free survival over extended follow-up of patients with advanced melanoma treated with immune checkpoint inhibitors in CheckMate 067
Regan, Meredith M.
Mantia, Charlene M.
Werner, Lillian
Tarhini, Ahmad A.
Larkin, James
Stephen Hodi, F.
Wolchok, Jedd
Postow, Michael A.
Stwalley, Brian
Moshyk, Andriy
Ritchings, Corey
Re, Sandra
van Dijck, Wim
McDermott, David F.
Atkins, Michael B.
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (11)

← 1 2 3 4 5 →